CN103893160A - 雷沙吉兰用于改善帕金森氏症 - Google Patents

雷沙吉兰用于改善帕金森氏症 Download PDF

Info

Publication number
CN103893160A
CN103893160A CN201310714021.5A CN201310714021A CN103893160A CN 103893160 A CN103893160 A CN 103893160A CN 201310714021 A CN201310714021 A CN 201310714021A CN 103893160 A CN103893160 A CN 103893160A
Authority
CN
China
Prior art keywords
patient
disease
parkinson
rasagiline
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201310714021.5A
Other languages
English (en)
Chinese (zh)
Inventor
鲁斯·利维
伊莱·伊亚尔
他玛·戈伦
希拉·奥伦
內姆·沙万里
孟德·尔韦斯
米瑞·本阿米
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of CN103893160A publication Critical patent/CN103893160A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201310714021.5A 2008-06-13 2009-06-12 雷沙吉兰用于改善帕金森氏症 Pending CN103893160A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13193608P 2008-06-13 2008-06-13
US61/131,936 2008-06-13
US18972408P 2008-08-22 2008-08-22
US61/189,724 2008-08-22

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2009801230031A Division CN102065687A (zh) 2008-06-13 2009-06-12 雷沙吉兰用于改善帕金森氏症

Publications (1)

Publication Number Publication Date
CN103893160A true CN103893160A (zh) 2014-07-02

Family

ID=41415378

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2009801230031A Pending CN102065687A (zh) 2008-06-13 2009-06-12 雷沙吉兰用于改善帕金森氏症
CN201310714021.5A Pending CN103893160A (zh) 2008-06-13 2009-06-12 雷沙吉兰用于改善帕金森氏症

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN2009801230031A Pending CN102065687A (zh) 2008-06-13 2009-06-12 雷沙吉兰用于改善帕金森氏症

Country Status (13)

Country Link
US (2) US20090312436A1 (enExample)
EP (2) EP2296462A4 (enExample)
JP (3) JP2011522892A (enExample)
CN (2) CN102065687A (enExample)
AU (2) AU2009258151A1 (enExample)
BR (1) BRPI0909894A2 (enExample)
CA (1) CA2727022A1 (enExample)
EA (1) EA201170018A1 (enExample)
IL (1) IL209131A0 (enExample)
MX (1) MX2010013766A (enExample)
NZ (1) NZ589445A (enExample)
WO (1) WO2009151625A1 (enExample)
ZA (1) ZA201008484B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110831606A (zh) * 2017-04-05 2020-02-21 克雷斯顿沃控股公司 治疗帕金森氏病(pd)和相关疾病的组合物和方法

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006014973A2 (en) * 2004-07-26 2006-02-09 Teva Pharmaceutical Industries, Ltd. Pharmaceutical dosage forms including rasagiline
CN101098685A (zh) * 2004-11-24 2008-01-02 特瓦制药工业有限公司 雷沙吉兰经口崩解组合物
JP5701485B2 (ja) * 2006-02-21 2015-04-15 テバ ファーマシューティカル インダストリーズ リミティド 多系統萎縮症の治療のためのラサギリンの使用
MX2008012781A (es) 2006-04-03 2008-10-14 Teva Pharma Uso de rasagilina para el tratamiento de sindrome de piernas inquietas.
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
US20090062400A1 (en) * 2007-09-05 2009-03-05 Laurence Oron Method of treating glaucoma using rasagiline
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
EP2234478A4 (en) * 2008-01-11 2013-01-23 Teva Pharma RASAGILINE FORMULATIONS, THEIR PREPARATION AND USE
US20100008983A1 (en) * 2008-06-10 2010-01-14 Muhammad Safadi Rasagiline soft gelatin capsules
NZ589547A (en) * 2008-06-19 2013-03-28 Teva Pharma Dried rasagiline base having a water content less than 0.5 % by weight
JP2011525489A (ja) * 2008-06-19 2011-09-22 テバ ファーマシューティカル インダストリーズ リミティド ラサリジン塩基の精製方法
US20100189791A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline malate formulation
DK2451771T3 (da) 2009-07-09 2014-09-08 Ratiopharm Gmbh Salte af rasagilin og farmaceutiske fremstillingsmåder heraf
EP2515891A4 (en) * 2009-12-22 2013-06-05 Teva Pharma 3-keto-N-propargyl-1-aminoindan
CA2806737A1 (en) * 2010-07-27 2012-02-02 Teva Pharmaceutical Industries Ltd. Dispersions of rasagiline citrate
EP2603212A4 (en) * 2010-07-27 2014-01-08 Teva Pharma USE OF RASAGILINE FOR THE TREATMENT OF SMOKING DISORDER
MX2013004598A (es) * 2010-10-26 2013-07-17 Teva Pharma Rasagilina enriquesida con deuterio.
CA2732440C (en) * 2011-02-23 2017-10-31 Universite Laval Cystamine analogues for the treatment of parkinson`s disease
EA201490756A1 (ru) * 2011-10-10 2014-09-30 Тева Фармасьютикал Индастриз, Лтд. Разагилина цитрамид
AU2012323349A1 (en) 2011-10-10 2014-05-22 Teva Pharmaceutical Industries Ltd. R(+)-N-formyl-propargyl-aminoindan
BR112014008552A2 (pt) 2011-10-10 2017-04-18 Teva Pharma r(+)-n-metil-propargilaminoindano
CA2882072A1 (en) 2012-08-17 2014-02-20 Teva Pharmaceutical Industries Ltd. Parenteral formulations of rasagiline
WO2015153629A1 (en) * 2014-04-01 2015-10-08 Teva Pharmaceutical Industries Ltd. Determination of single nucleotide polymorphisms useful to predict response for rasagiline
US10292947B2 (en) * 2016-03-26 2019-05-21 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions for N-propargylamine derivative
AU2019427489B2 (en) * 2019-01-28 2025-03-13 Mitochondria Emotion, Inc. Mitofusin activators and methods of use thereof
GB202109826D0 (en) * 2021-07-07 2021-08-18 Bial Portela & Ca Sa Treatment regimens for early idiopathic parkinson's disease

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744500A (en) * 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
CN1031995C (zh) * 1991-01-02 1996-06-12 奥韦特有限公司 N-炔丙基-1-氨基茚满的r-对映体的制法
IL112819A (en) * 1991-10-16 2001-11-25 Teva Pharma Fluorinated 1-aminoindan compounds and a process for their preparation
IL115357A (en) * 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en) * 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
DE69738275T2 (de) * 1996-12-18 2008-08-28 Teva Pharmaceutical Industries Ltd. Aminoindanderivate
AU2002319615A1 (en) * 2001-07-20 2003-03-03 Mount Sinai School Of Medicine Of New York University Methods for diagnosing and treating alzheimer's disease and parkinson's disease
KR100614862B1 (ko) * 2001-12-28 2006-08-22 다케다 야쿠힌 고교 가부시키가이샤 배뇨 장애 예방제/치료제
ES2588780T3 (es) * 2002-11-15 2016-11-04 Teva Pharmaceutical Industries Limited Uso de rasagilina con o sin riluzol para el tratamiento de la esclerosis lateral amiotrófica
US20050031651A1 (en) * 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
WO2006014973A2 (en) * 2004-07-26 2006-02-09 Teva Pharmaceutical Industries, Ltd. Pharmaceutical dosage forms including rasagiline
CN101098685A (zh) * 2004-11-24 2008-01-02 特瓦制药工业有限公司 雷沙吉兰经口崩解组合物
CA2901244A1 (en) * 2005-02-23 2006-08-31 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations of improved content uniformity
US7491847B2 (en) * 2005-11-17 2009-02-17 Teva Pharmaceutical Industries, Ltd. Methods for isolating propargylated aminoindans
US7572834B1 (en) * 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
JP5701485B2 (ja) * 2006-02-21 2015-04-15 テバ ファーマシューティカル インダストリーズ リミティド 多系統萎縮症の治療のためのラサギリンの使用
US9066903B2 (en) * 2006-02-28 2015-06-30 The United States Of America As Represented By The Department Of Veterans Affairs Pharmacological treatment of Parkinson's disease
CN101032474B (zh) * 2006-03-06 2011-02-16 重庆医药工业研究院有限责任公司 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
MX2008012781A (es) * 2006-04-03 2008-10-14 Teva Pharma Uso de rasagilina para el tratamiento de sindrome de piernas inquietas.
EP1892233A1 (de) * 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
PT2101569E (pt) * 2006-12-14 2012-01-13 Teva Pharma Base de rasagilina sólida cristalina
NZ577623A (en) * 2006-12-14 2011-05-27 Teva Pharma Tannate salt of rasagiline
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
WO2009032202A1 (en) * 2007-08-29 2009-03-12 Nuon Therapeutics, Inc. Treatment of brain disorders
US20090062400A1 (en) * 2007-09-05 2009-03-05 Laurence Oron Method of treating glaucoma using rasagiline
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
EP2234478A4 (en) * 2008-01-11 2013-01-23 Teva Pharma RASAGILINE FORMULATIONS, THEIR PREPARATION AND USE
US20100008983A1 (en) * 2008-06-10 2010-01-14 Muhammad Safadi Rasagiline soft gelatin capsules
JP2011525489A (ja) * 2008-06-19 2011-09-22 テバ ファーマシューティカル インダストリーズ リミティド ラサリジン塩基の精製方法
NZ589547A (en) * 2008-06-19 2013-03-28 Teva Pharma Dried rasagiline base having a water content less than 0.5 % by weight
DE102008064061A1 (de) * 2008-12-19 2010-06-24 Ratiopharm Gmbh Feste Zusammensetzung mit dem Wirkstoff Rasagilin
US20100189791A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline malate formulation
EP2485722A1 (en) * 2009-10-09 2012-08-15 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of progressive supranuclear palsy
EP2515891A4 (en) * 2009-12-22 2013-06-05 Teva Pharma 3-keto-N-propargyl-1-aminoindan

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
谢单丹: "抗帕金森病药 甲磺酸雷沙吉兰(rasagiline mesylate)", 《世界临床药物》 *
马建芳等: "单胺氧化酶B型抑制剂治疗帕金森病的新进展", 《神经病学与神经康复学杂志》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110831606A (zh) * 2017-04-05 2020-02-21 克雷斯顿沃控股公司 治疗帕金森氏病(pd)和相关疾病的组合物和方法

Also Published As

Publication number Publication date
AU2016259315A1 (en) 2016-12-01
EA201170018A1 (ru) 2011-08-30
NZ589445A (en) 2013-06-28
US20090312436A1 (en) 2009-12-17
BRPI0909894A2 (pt) 2015-07-28
JP2017081938A (ja) 2017-05-18
WO2009151625A1 (en) 2009-12-17
EP2666356A1 (en) 2013-11-27
MX2010013766A (es) 2011-03-15
US20140243418A1 (en) 2014-08-28
AU2009258151A1 (en) 2009-12-17
EP2296462A1 (en) 2011-03-23
JP2011522892A (ja) 2011-08-04
JP2015096532A (ja) 2015-05-21
EP2296462A4 (en) 2011-06-15
CA2727022A1 (en) 2009-12-17
CN102065687A (zh) 2011-05-18
ZA201008484B (en) 2012-05-30
IL209131A0 (en) 2011-01-31

Similar Documents

Publication Publication Date Title
CN103893160A (zh) 雷沙吉兰用于改善帕金森氏症
Duvoisin et al. Parkinson's disease: A guide for patient and family
Fox et al. The Movement Disorder Society evidence‐based medicine review update: treatments for the motor symptoms of Parkinson's disease
Priebe et al. Clinical assessment of spasticity in spinal cord injury: a multidimensional problem
Brooks Diagnosis and management of atypical parkinsonian syndromes
CN110012661A (zh) 普利多匹定用于治疗肌张力障碍的用途
Ibrahim et al. Muslim prayer movements as an alternative therapy in the treatment of erectile dysfunction: a preliminary study
Rewar A systematic review on Parkinson's disease (PD)
TW200829241A (en) Treatment of parkinson's disease
KR20250034521A (ko) 실조증을 치료하기 위한 릴루졸 전구약물의 용도
Van Wegen et al. Sensor assisted self-management in Parkinson's disease: A feasibility study of ambulatory posture detection and feedback to treat stooped posture
Rodriguez-Larrad et al. Loss of benefits after cessation of exercise interventions in nursing home residents: randomized controlled trial follow-up
US20230372335A1 (en) TREATMENT OF COGNITIVE IMPAIRMENT WITH A CNS-PENETRANT sGC STIMULATOR
Higuchi et al. Does fear of falling relate to low physical function in frail elderly persons?: Associations of fear of falling, balance, and gait
WO2024216046A1 (en) Methods of treating anhedonia
Gancher Scales for the assessment of movement disorders
WO2024216061A1 (en) Methods of treating depression and anhedonia
Hoeppner et al. Postural balance and self-reported exercise in older adults
Raj et al. Does Proprioception of knee improve after various forms of Training in Osteoarthritis of Knee?
Vernon Parkinson's disease
Sun et al. RETRACTED ARTICLE: Clinical effect of duloxetine on improving osteoporosis low back pain in older adults
Mandelcorn et al. A preliminary study of the efficacy of ondansetron in the treatment of ataxia, poor balance and incoordination from brain injury
Roller et al. Disease state management: Parkinson's disease
MESHACK THE EFFECTS OF WEIGHTS ON THE AMPLITUDE AND FREQVENCY OF POSTURAL EWND TREMOR IN PEOPLE WITH PARKINSON'S DISEASE
Cert et al. The Influence of Centralization and Directional Preference on Spinal Control in People with Nonspecific Neck Pain: A Single Arm Clinical Trial

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20140702